Description:
Ethaselen, also known as BBSKE, is a novel organoselenium thioredoxin reductase inhibitor, is currently being investigated in a phase I clinical trial in China. Ethaselen enhanced the efficacy of radiation therapy both in vivo and in vitro without observable toxicity. BBSKE was found to suppress irradiation-induced activation dramatically when using A549 cells stably transfected with luciferase reporter. Ethaselen is a potentially promising agent for the treatment of patients with NSCLC clinically.
Molecular Formula:
C16H12N2O2Se2
Canonical SMILES:
C1=CC=C2C(=C1)C(=O)N([Se]2)CCN3C(=O)C4=CC=CC=C4[Se]3
InChI:
InChI=1S/C16H12N2O2Se2/c19-15-11-5-1-3-7-13(11)21-17(15)9-10-18-16(20)12-6-2-4-8-14(12)22-18/h1-8H,9-10H2
InChIKey:
SFFSGPCYJCMDJM-UHFFFAOYSA-N
Appearance:
white solid powder
Synonyms:
1,2-[bis(1,2-benzisoselenazolone-3(2H)-ketone)]ethane; BBSKE Más detalles se encuentran
aquí
details